Project Grant R01CA296573
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $736K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $716,521 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Sloan-Kettering Institute for Cancer Research in New York. The 5-year grant, awarded on August 25, 2025, supports the development and evaluation of DLL3-targeted, IL18-secreting chimeric antigen receptor (CAR) T cells for the treatment of small cell lung cancer (SCLC). The research aims to determine the safety and preliminary efficacy of this novel immunotherapy...
- The Sloan-Kettering Institute for Cancer Research was awarded a $176,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant will support research to explore a novel antibody-drug conjugate (ADC) strategy to block MYC protein production in neuroblastoma. The two-year project aims to develop innovative cancer treatment approaches that could transform healthcare for military service members and the broader public. As a...
- The National Cancer Institute (NCI) awarded a $487,393 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to the Sloan-Kettering Institute for Cancer Research in New York, NY, effective December 1, 2024 through November 30, 2029. The grant supports research to determine the role of RAD52, HELQ, and POLQ proteins in backup DNA double-strand break repair pathways, which are critical for the survival of homologous recombination deficient (HRD) cancer cells. The research aims to...
- Sloan-Kettering Institute For Cancer Research was awarded a $796,500 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period of July 15, 2023 through July 14, 2026. The grant will support research to develop novel tools to improve responses to DNA-damaging therapeutics in metastatic breast cancer. As the prime recipient, Sloan-Kettering Institute For Cancer Research will leverage its expertise in cancer biology,...
- The National Cancer Institute (NCI) awarded a $730,398 project grant under the Cancer Treatment Research program (CFDA 93.395) to the Sloan-Kettering Institute for Cancer Research. The 5-year grant, which commenced on September 1, 2025, aims to leverage radiation-induced senescence and PTPN2 inhibition to enhance immune-mediated tumor control in rectal cancer. The research seeks to develop non-surgical treatment strategies that prioritize organ preservation and minimize lifelong morbidities...
- The Sloan-Kettering Institute for Cancer Research was awarded a $205,700 Project Grant by the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), to conduct research on targeting chromosomal instability in the evolution of resistance to matched therapies against colorectal cancer. The research aims to understand how intrinsic tumor features enable increased chromosomal instability, leading to rapid resistance to targeted cancer therapies. The project...
- The Defense Health Agency awarded a $619,500 Project Grant to the Sloan-Kettering Institute for Cancer Research, a non-profit organization in New York, NY. The grant is funded through the Military Medical Research and Development (CFDA 12.420) program and will support research to investigate the immunogenicity and targeting of shared neoantigens in adenoid cystic cancer over a 3-year period from September 1, 2023 to August 31, 2026. The research aims to transform health care for Service...
- The National Cancer Institute (NCI) awarded a $482,236 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Sloan-Kettering Institute for Cancer Research in New York. The grant supports a biomarker-intensive, investigator-initiated Phase 2 clinical trial to evaluate the safety and efficacy of combining the antibody-drug conjugate trastuzumab deruxtecan (T-DXD) and the anti-EGFR antibody cetuximab for treating chemorefractory HER2-low metastatic colorectal cancer. The...
- This federal Project Grant award of $1,056,000.00 from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports research conducted by the Sloan-Kettering Institute for Cancer Research in New York to overcome resistance to targeted therapies in breast cancer. The research aims to elucidate the mechanisms of cancer cell plasticity and therapy resistance, focusing on the roles of genomic instability, effector pathways, and long-term response to targeted treatments. Through a...
- This federal Project Grant award of $402,600, provided by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research), supports the development of novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 snRNP complex for the treatment of acute myeloid leukemia (AML). The Sloan-Kettering Institute for Cancer Research, a leading nonprofit cancer research organization, is the awardee for this 5-year project, which commenced on April 3, 2025. The goal is to advance these...